在心力衰竭患者中使用心房分流装置后的安全性和有效性:系统性审查和元分析
Lihua Gao1, Zhenze Yu1, Pengfei Wang1
1Cardiac Department, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, PR China.
Current problems in cardiology
|May 26, 2025
概括
心房分流装置 (ASD) 是心力衰竭 (HF) 患者的安全选择,可以改善症状和功能能力. 降低射出分数或高NT-proBNP患者受益最多,特别是没有高血压,糖尿病或心房动的患者.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭管理的管理
背景情况:
- 对于心力衰竭 (HF) 患者的心房分流装置 (ASD) 存在有限的数据.
- 这阻碍了对HF管理的最终治疗建议.
- 进行了元回归分析,以确定ASD的最佳候选患者.
研究的目的:
- 为了评估心脏衰竭 (HF) 患者心房分流装置 (ASD) 的安全性和有效性.
- 为了确定预测ASD植入更大的好处的患者特征.
- 为临床决策提供数据驱动的洞察力,用于对高频的ASD使用进行临床决策.
主要方法:
- 在PubMed,EMBASE和Cochrane数据库中进行了系统的文献搜索.
- 包含522名患者的8项研究被纳入了元分析和元回归.
- 随机效应比例元分析和元回归被用于分析终点和共变量.
主要成果:
- 心房分流装置 (ASD) 在心力衰竭 (HF) 患者中显示出较低的死亡率 (1.9%).
- 在NYHA功能类,6分钟步行距离 (6MWD) 和KCCQ分数中观察到显著的改善.
- 超回归确定年龄,高血压,糖尿病和心房与较高的NYHA类相关;高血压和高LVEF与功能改善较差相关,而高NT-proBNP表明更好的结果.
结论:
- 心房分流装置 (ASD) 是一种安全的治疗选择,可以缓解心力衰竭 (HF) 患者的症状.
- 降低射出分数 (EF) 或升高NT-proBNP水平的患者可能会经历更大的症状缓解.
- 这项研究表明,没有并发高血压,糖尿病或心房的患者可以从ASD植入中获得更大的益处.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
527
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
527
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:22Heart Failure VI: Adjunct Therapies
40
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
40
01:25Aortic Regurgitation III: Medical Management
54
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
54
01:26Mitral Stenosis III: Medical Management
31
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
31
01:22Heart Failure Drugs: β-Blockers
446
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
446